Friday, July 7, 2017
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis. The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara® *(ustekinumab) in psoriasis ,. The updated label also includes use of Cosentyx to treat moderate-to-severe scalp psoriasis – one of the most difficult-to-treat forms of psoriasis, which affects approximately 60 million people worldwide,. The updated label is based on the proven efficacy and consistent safety profile of Cosentyx.